La vendita allo scoperto per Aethlon Medical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Aethlon Medical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Aethlon Medical (NASDAQ:AEMD) Azioni, Report sulle vendite allo scoperto

Aethlon Medical

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Aethlon Medical Inc

<h3>Gainers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares rose 129.5% to $6.61 during Tuesday's after-market session. The market value of their outstanding shares is at $4.3 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 60.8% to $1.28. The market value of their outstanding shares is at $2.6 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares increased by 34.26% to $1.09. The company's market cap stands at $1.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 13.98% to $2.2. The market value of their outstanding shares is at $10.8 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock moved upwards by 12.12% to $0.37. The company's market cap stands at $7.6 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) shares moved upwards by 10.88% to $2.63. The market value of their outstanding shares is at $84.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 55.6% to $0.24 during Tuesday's after-market session. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares declined by 14.31% to $6.11. The market value of their outstanding shares is at $4.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 12.69% to $0.24. The company's market cap stands at $1.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock declined by 12.26% to $0.62. The market value of their outstanding shares is at $2.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 11.39% to $3.27. The company's market cap stands at $2.9 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock decreased by 8.36% to $0.82. The company's market cap stands at $19.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABVC

AEMD

ANIX

ATNF

NAOV

NAYA

PTIX

REVB

SLRX

VERO

VINC

WORX

12 Health Care Stocks Moving In Tuesday's After-Market Session

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) with a Buy and maintains $7 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Aethlon Medical, Maintains $7 Price Target

Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier&#xAE; Beyond Virology and Oncology
Results Support Further Evaluation of the Hemopurifier&#xAE;&nbsp;as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys
SAN DIEGO, March 10, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4378620-1&amp;h=3653404512&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Faethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOmI3YWI2N2Q2OWRiZjI1MjAzMDg1MWYzYTRmNWQ4YjYxOjY6NjNiYTpmNzBkM2E2YjIwNTc2MDI1ZjRlZmJiMWVmMzQ5Mzg2MDJmMjk4M2EwZTcwOGM5NDUyOTJiNTY1NWFlNjFlYzhhOnA6VDpO&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in&nbsp;the peer-reviewed journal Transplant Immunology (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4378620-1&amp;h=1949581366&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fdoi.org%2F10.1016%2Fj.trim.2025.102215___.YXAzOmFldGhsb246YTpvOjdmZGM3ZDI2M2E4NTU5MWQxY2Q4MmFkODkzNDUwYzZjOjY6NmNjYTo1OGI0ZWE0NTFhZDY1NGY0OGQ5ZWRjZGM5NmZlYWVkNjNhMzAzZmM5ZGQzZTZiZmNlMjIyYWM5NGI1NjdhODFkOnA6VDpO&amp;a=https%3A%2F%2Fdoi.org%2F10.1016%2Fj.trim.2025.102215">https://doi.org/10.1016/j.trim.2025.102215</a>) on February 28, 2025, entitled, " A lectin affinity plasmapheresis device removes extracellular vesicles and microRNAs from renal perfusates following controlled oxygenated rewarming of discarded donor kidneys."
Aethlon Medical's Hemopurifier&#xAE;&nbsp;is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids. Its capabilities have potential applications in oncology and infectious diseases, and organ transplantation.

Biotech

General

Aethlon Medical Publishes Preclinical Data On The Hemopurifier In Transplant Immunology Journal Entitled, " A Lectin Affinity Plasmapheresis Device Removes Extracellular Vesicles And MicroRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming Of Discarded Donor Kidneys."

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.20) by 35 percent. This is a 90.51 percent increase over losses of $(1.37) per share from the same period last year.

Earnings

Earnings Beats

Aethlon Medical Q3 EPS $(0.13) Beats $(0.20) Estimate

ACRE

AEIS

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CGNX

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

WIIM

Aethlon Medical shares are trading higher after the company announced it treated its first patient in the Australian Hemopurifier cancer trial.

Aethlon Medical Announces A Milestone With The Treatment Of The First Patient With The Hemopurifier In Its Australian Safety, Feasibility And Dose-Finding Clinical Trial of the Hemopurifier

<a href="https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004">https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004</a>
&nbsp;
A new case of Mpox has been confirmed in the UK, the UK Health Security Agency (UKHSA) has said.
The latest case of Clade Ib Mpox is the seventh confirmed case since October 2024 after a sixth patient <a href="https://www.manchestereveningnews.co.uk/news/uk-news/new-mpox-case-detected-uk-30823540">was admitted to hospital last week</a>.
<a href="https://www.gov.uk/government/news/ukhsa-detects-first-case-of-clade-ib-mpox?utm_medium=email&amp;utm_campaign=govuk-notifications-topic&amp;utm_source=d72f8bd1-0516-4336-9e7d-b4f8a791ba9a&amp;utm_content=immediately">The UKHSA says</a> the infected patient had recently travelled to Uganda and that the risk to the UK population "remains low". The UKHSA and <a href="https://www.manchestereveningnews.co.uk/all-about/nhs">NHS</a> says it will not be disclosing any further details about the infected person.
Professor Susan Hopkins, Chief Medical Adviser at UKHSA, said: "The risk to the UK population remains low. Close contacts have been identified and offered appropriate advice in order to reduce the chance of further spread."
Mpox, previously known as monkeypox, is a rare infection most commonly found in parts of central and east Africa.
There is currently community transmission of the virus in Uganda, which has so far recorded <a href="https://www.afro.who.int/countries/uganda/publication/mpox-outbreak-uganda-situation-update-22-january-2025">2,209 confirmed Mpox cases</a> and 13 deaths since July 2024.
The Clade Ib variant is a new form of the virus, the which the World Health Organisation (WHO) declared as a global health emergency in August.
WHO says common symptoms of Mpox include a skin rash or lesions which can last two to four weeks, as well as a fever, headache, muscle aches, back pain, low energy and swollen lymph nodes.
<a href="https://www.nhs.uk/conditions/mpox/">The NHS says</a> Mpox can be passed on from person to person through:
Close physical contact with Mpox blisters or scabs
Touching clothing, bedding or towels used by someone with Mpox
The coughs or sneezes of a person with Mpox when they're close to you

APDN

CMRX

GOVX

MRNA

TNXP

VRAX

"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News

<a href="https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/">https://www.washingtonpost.com/health/2025/01/16/bird-flu-testing-patients-in-hospital/</a>
&nbsp;
The Centers for Disease Control and Prevention says hospitals treating people for the flu should test them for avian influenza within 24 hours.

NVAX

'As Bird Flu Affects More People And Animals, CDC Urges Faster Testing' - Washington Post

<a href="https://ldh.la.gov/news/H5N1-death#:~:text=The%20Louisiana%20Department%20of%20Health,to%20have%20underlying%20medical%20conditions.">https://ldh.la.gov/news/H5N1-death#:~:text=The%20Louisiana%20Department%20of%20Health,to%20have%20underlying%20medical%20conditions.</a>
&nbsp;
<h3>Current general public health risk remains low</h3>
January 06, 2025
The Louisiana Department of Health reports the patient who had been hospitalized with the first human case of highly pathogenic avian influenza (HPAI), or H5N1, in Louisiana and the U.S. has died. The patient was over the age of 65 and was reported to have underlying medical conditions. The patient contracted H5N1 after exposure to a combination of a non-commercial backyard flock and wild birds.&nbsp;
LDH&#39;s extensive public health investigation has identified no additional H5N1 cases nor evidence of person-to-person transmission. This patient remains the only human case of H5N1 in Louisiana.&nbsp;
The Department expresses its deepest condolences to the patient&#39;s family and friends as they mourn the loss of their loved one. Due to patient confidentiality and respect for the family, this will be the final update about the patient.&nbsp;
While the current public health risk for the general public remains low, people who work with birds, poultry or cows, or have recreational exposure to them, are at higher risk.&nbsp;
The best way to protect yourself and your family from H5N1 is to avoid sources of exposure. That means avoiding direct contact with wild birds and other animals infected with or suspected to be infected with bird flu viruses.&nbsp;
Protecting yourself and others from H5N1 infection
<ul>
<li>Do not touch sick or dead animals or their droppings and do not bring sick wild animals into your home.</li>
<li>Keep your pets away from sick or dead animals and their feces.</li>
<li>Do not eat uncooked or undercooked food. Cook poultry, eggs and other animal products to the proper temperature and prevent cross-contamination between raw and cooked food.</li>
<li>Avoid uncooked food products such as unpasteurized raw milk or cheeses from animals that have a suspected or confirmed infection.</li>
<li>If you work on poultry or dairy farms, talk to your provider about getting your seasonal flu vaccination. It will not prevent infection with avian influenza viruses, but it can reduce the risk of coinfection with avian and flu viruses.</li>
<li>Report dead or sick birds or animals to the USDA toll-free at 1-866-536-7593 or the Louisiana Department of Agriculture and Forestry Diagnostic Lab at 318-927-3441.</li>
</ul>
If you have been exposed to sick or dead birds or other animals or work on a farm where avian influenza has been detected, watch for respiratory symptoms or conjunctivitis. If you develop symptoms within 10 days after exposure to sick or dead animals, tell your healthcare provider that you have been in contact with sick animals and are concerned about avian influenza. This will help them give you appropriate advice on testing and treatment. Stay home and away from others while you have symptoms.

NNVC

'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares moved upwards by 228.8% to $0.92 during Thursday's pre-market session. The market value of their outstanding shares is at $19.1 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares moved upwards by 136.44% to $1.09. The company's market cap stands at $9.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock rose 26.79% to $3.88. The company's market cap stands at $32.8 million. </li>
<li>MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) shares increased by 25.5% to $23.13. The company's market cap stands at $772.9 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock rose 23.59% to $0.21. The market value of their outstanding shares is at $23.2 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares moved upwards by 18.49% to $0.67. The market value of their outstanding shares is at $41.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares decreased by 82.1% to $1.9 during Thursday's pre-market session. The company's market cap stands at $306.9 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares decreased by 43.43% to $4.3. The company's market cap stands at $153.8 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 12.49% to $0.23. The company's market cap stands at $8.3 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) shares decreased by 11.88% to $2.45. The market value of their outstanding shares is at $64.8 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares decreased by 11.3% to $3.14. The market value of their outstanding shares is at $42.3 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock declined by 10.46% to $0.77. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDMD

CALC

CBUS

CRIS

CTCX

NMRA

PASG

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/BTC-USD">pre-market trading</a>.
This surge is attributed to a significant rise in Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price, which reached $96,578.38, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
MicroStrategy shares jumped 5.5% to $305.43 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Alternus Clean Energy Inc  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) gained 153.7% to $1.99 in pre-market trading after falling around 15% on Tuesday.</li>
<li>Alset Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) gained 139.2% to $2.44 in pre-market trading after dipping 20% on Tuesday.</li>
<li>Creative Media &amp; Community Trust Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) rose 97.2% to $0.4440 in pre-market trading after gaining around 39% on Tuesday.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) rose 71% to $2.24 in pre-market trading after climbing around 15% on Tuesday.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) gained 58.6% to $0.6346 in pre-market trading after surging around 18% on Tuesday.</li>
<li>Digimarc Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMRC#NASDAQ">DMRC</a>) gained 55.9% to $58.40 in pre-market trading.</li>
<li>VerifyMe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) gained 55.1% to $2.11 in pre-market trading after gaining 72% on Tuesday.</li>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) gained 50.3% to $2.30 in pre-market trading after gaining around 8% on Tuesday.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) gained 22.1% to $0.2102 in pre-market trading after gaining around 7% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Baird Medical Investment Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) fell 35.7% to $4.89 in pre-market trading after jumping 624% on Tuesday.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) shares tumbled 24.5% to $0.4540 in pre-market trading after jumping 107% on Tuesday.</li>
<li>Sidus Space, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) declined 21.6% to $3.84 in pre-market trading.</li>
<li>Genie Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) fell 15.9% to $13.11 in pre-market trading.</li>
<li>NRx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares dipped 14.5% to $1.88 in pre-market trading after jumping 44% on Tuesday.</li>
<li>Park Ha Biological Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHH#NASDAQ">PHH</a>) shares fell 14.2% to $5.40 in pre-market trading after climbing 30% on Tuesday.</li>
<li>Twin Vee Powercats Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) fell 13.6% to $0.4751 in today's pre-market trading after jumping more than 51% on Tuesday.</li>
<li>Clean Energy Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETY#NASDAQ">CETY</a>) shares fell 13.5% to $0.53 in pre-market trading after gaining around 5% on Tuesday.</li>
<li>Aethlon Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) dipped 13.3% to $0.75 in pre-market trading after jumping 30% on Tuesday.</li>
<li>CeriBell Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBLL#NASDAQ">CBLL</a>) fell 10.3% to $23.21 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42740135/how-to-earn-500-a-month-from-alphabet-stock">How To Earn $500 A Month From Alphabet Stock</a></li>
</ul>

$BTC

ALCE

CBLL

CETY

CGBS

CMCT

DMRC

MSTR

NRXP

ORIS

SIDU

VEEE

VRME

VSME

Why MicroStrategy Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares rose 114.6% to $1.03 during Friday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares increased by 67.34% to $5.79. The market value of their outstanding shares is at $744.9 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 62.19% to $3.99. The company's market cap stands at $3.3 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares increased by 37.77% to $0.6. The company's market cap stands at $8.3 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares rose 29.25% to $30.75. The market value of their outstanding shares is at $162.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 16.55% to $3.45. The market value of their outstanding shares is at $3.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock declined by 53.1% to $0.16 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) stock decreased by 38.5% to $1.23. The market value of their outstanding shares is at $77.1 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares declined by 32.43% to $0.44. The market value of their outstanding shares is at $2.2 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 21.86% to $0.93. The company's market cap stands at $44.9 million. </li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares declined by 20.14% to $82.61. The company's market cap stands at $366.9 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares decreased by 17.71% to $2.51. The company's market cap stands at $10.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

GALT

HSDT

HUMA

ISPC

MNPR

MTEM

QNRX

SSKN

12 Health Care Stocks Moving In Friday's Pre-Market Session

Aethlon Medical shares are trading higher after the company highlighted Hemopurifier's 99% in vitro capture of the H5N1 bird flu virus.

Aethlon Medical Highlights Hemopurifier's 99% In Vitro Capture Of H5N1 Bird Flu Virus, Showcasing Potential For Treating Severe Infections Amid Rising Cases And Emergency Declarations In The U.S.

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares moved upwards by 376.8% to $3.19 during Thursday's pre-market session. The market value of their outstanding shares is at $13.7 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock rose 50.2% to $18.4. The company's market cap stands at $2.0 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 38.56% to $2.12. The market value of their outstanding shares is at $1.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 35.45% to $1.49. The market value of their outstanding shares is at $76.7 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock rose 33.78% to $9.98. The company's market cap stands at $578.3 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock rose 26.21% to $4.77. The market value of their outstanding shares is at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 35.1% to $0.43 during Thursday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 26.75% to $2.41. The market value of their outstanding shares is at $10.1 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock fell 20.01% to $11.2. The company's market cap stands at $681.5 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 17.87% to $3.31. The market value of their outstanding shares is at $29.5 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 13.93% to $3.4. The market value of their outstanding shares is at $3.2 million. </li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock fell 12.85% to $390.0. The market value of their outstanding shares is at $100.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

MESO

MRKR

MYNZ

OMER

PLRX

PLRZ

VRTX

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.47% to 42,525.10 while the NASDAQ rose 0.84% to 19,554.71. The S&amp;P 500 also rose, gaining, 0.62% to 5,908.52.
Check This Out: <a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 1.1% on Thursday.
In trading on Thursday, health care shares fell by 0.7%.
Top Headline
Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) posted better-than-expected earnings for its first quarter, while sales missed expectations.
The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares shot up 532% to $13.85.</li>
<li>Shares of Trio Petroleum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>)got a boost, surging 358% to $3.7550 after the company announced it will acquire the oil and gas assets in a heavy oil region of Saskatchewan, Canada for approximately $1.4 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares were also up, gaining 281% to $2.55 after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares dropped 61% to $0.3185 as the company reported the pricing of public offering.</li>
<li>Shares of Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) were down 38% to $0.4070.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 43% to $1.15.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $70.78 while gold traded down 1.7% at $2,607.90.
Silver traded down 4.6% to $29.315 on Thursday, while copper fell 1.5% to $4.0955.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1.7%, Germany's DAX fell 1.3% and France's CAC 40 declined 1.3%. Spain's IBEX 35 Index fell 1.7%, while London's FTSE 100 fell 1.3%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 0.56%, China's Shanghai Composite Index declining 0.36% and India's BSE Sensex falling 1.20%.
Economics
<ul>
<li>The Philadelphia Fed Manufacturing Index dipped to -16.4 in December compared to -5.5 in November and down from market expectations of 3.</li>
<li>The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.</li>
<li>U.S. existing home sales gained by 4.8% from the previous month to an annualized rate of 4.15 million in November.</li>
<li>U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

LITM

PRFX

TPET

WLGS

US Stocks Higher, Micron Reports Downbeat Sales

Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/SGMO/news">pre-market trading</a>.
Astellas and Sangamo Therapeutics disclosed Capsid license agreement to deliver genomic medicines for neurological diseases.
Sangamo Therapeutics shares jumped 19.5% to $2.81 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) gained 219.5% to $6.39 in pre-market trading after jumping 54% on Wednesday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) climbed 170% to $2.13 in pre-market trading after declining over 50% on Wednesday.</li>
<li>AppTech Payments Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) gained 170% to $1.03 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) gained 68% to $3.55 in pre-market trading after dropping 26% on Wednesday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 44.5% to $17.70 in pre-market trading. Mesoblast&#8217;s RYONCIL became the first FDA-approved mesenchymal stromal cell therapy in the U.S.</li>
<li>Elevai Labs Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 38.6% to $2.98 in pre-market trading after gaining 9% on Wednesday.</li>
<li>Dallasnews Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) gained 38% to $6.72 in pre-market trading after falling 5% on Wednesday.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) rose 28% to $2.68 in pre-market trading after jumping 44% on Wednesday.</li>
<li>XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) gained 24.2% to $2.67 in pre-market trading after dipping more than 90% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 40.5% to $0.4847 in pre-market trading after jumping 348% on Wednesday.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) declined 36.4% to $0.42 in pre-market trading after jumping more than 80% on Wednesday.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) shares fell 20.5% to $6.00 in pre-market trading.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares dipped 18.6% to $63.50 in pre-market trading as the company posted downbeat quarterly results and lowered FY25 outlook.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) fell 18.5% to $0.5213 in today's pre-market trading after jumping 52% on Wednesday.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) dipped 15.6% to $87.60 in pre-market trading. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
<li>Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) fell 15.6% to $2.00 in pre-market trading after surging 39% on Wednesday.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares fell 14.5% to $2.95 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) fell 14.3% to $0.3008 in pre-market trading following a 30% plunge on Wednesday.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) fell 14.2% to $5.10 in pre-market trading after declining 5% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Pre-Market Outlook

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

NVNI

PTPI

QNTM

SGMO

SLXN

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Press Releases

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Small Cap

Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

Comments

Aethlon Medical

Vendite allo scoperto

Aethlon Medical (NASDAQ:AEMD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO